StreetInsider.com News Articles

Stryker (SYK) PT Lowered to $317 at BMO Capital Following Investor Conference Commentary

Wed, 09 Sep 2026 08:09:09 -0400

(Updated - September 9, 2026 8:09 AM EDT)

BMO Capital analyst Joanne Wuensch lowered the price target on Stryker (NYSE: SYK) to $317.00 (from $369.00) while maintaining an Outperform rating.

The analyst commented: "Updating Estimates Following Investor Conference Commentary; Following the company's comments at a competitor conference this week, we are updating our estimates for SYK. We lower our Q3 sales/EPS by $46 million/$0.01, now forecasting 10.2% organic growth. Overall, our 2026 estimates come down by $71 million and we now forecast 2026 organic growth of 8.4% (Q4 11.1% organic growth), compared with organic sales growth guidance of 8.3% to 9.3%. Our

Stryker (SYK) PT Lowered to $317 at BMO Capital Following Investor Conference Commentary

Wed, 09 Sep 2026 08:09:09 -0400

(Updated - September 9, 2026 8:09 AM EDT)

BMO Capital analyst Joanne Wuensch lowered the price target on Stryker (NYSE: SYK) to $317.00 (from $369.00) while maintaining an Outperform rating.

Stryker (SYK) PT Lowered to $317 at BMO Capital

Wed, 09 Sep 2026 07:56:40 -0400

BMO Capital analyst Joanne Wuensch lowered the price target on Stryker (NYSE: SYK) to $317.00 (from $369.00) while maintaining a Outperform rating.

Stryker (SYK) PT Lowered to $348 at Wells Fargo

Wed, 09 Sep 2026 05:53:16 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Stryker (NYSE: SYK) to $348.00 (from $418.00) while maintaining a Overweight rating.

The analyst comments "We hosted SYK at the 2026 Wells Fargo Healthcare Conference in Boston. Joining us from the company were Preston Wells, CFO and Nick Mead, VP of Investor Relations. We highlight key takeaways below. Updating our estimates. We are lowering our 2026 revenue estimate to $27,209MM from $27,325 (+8.5% org.) implying organic revenue growth of 8.1% which sits below SYK's guidance of 8.3%-9.3%. Our Q3 revenue estimate now assumes organic growth of 8.9% vs. 10.1%, previously. Our

Stryker (SYK) PT Lowered to $348 at Wells Fargo

Wed, 09 Sep 2026 05:53:16 -0400

Wells Fargo analyst Larry Biegelsen lowered the price target on Stryker (NYSE: SYK) to $348.00 (from $418.00) while maintaining a Overweight rating.

Form 3 STRYKER CORP For: Sep 01 Filed by: Baculik Emily Kay

Tue, 08 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260908/27036630.html

Supply chain woes send Stryker stock tumbling 7.7%

Tue, 08 Sep 2026 11:05:30 -0400

Investing.com -- Stryker Corp. shares dropped as much as 7.7% on Tuesday morning after company executives discussed ongoing problems in its peripheral vascular and joint replacement operations at an industry conference.

The company presented at the Wells Fargo Healthcare Conference, where Chief Financial Officer Preston Wells addressed issues affecting the business.

Wells explained that a manufacturing problem continues to prevent the company from maintaining full inventory supply to customers. The issue also limits the company’s ability to pursue new business opportunities. The company had expected to resolve this problem in the third quarter.

"What we’re seeing is that is continuing into the

Stryker (SYK) Falls with Conf Ongoing

Tue, 08 Sep 2026 10:21:51 -0400

Stryker (NYSE: SYK) Falls with Conf Ongoing

-5%
Stryker (NYSE: SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported.
Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations.

Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Fri, 04 Sep 2026 18:32:00 -0400

Portage, Michigan, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor, as previously reported.

Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will now participate in a fireside chat session at 10:15 a.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations.

About Stryker

Stryker is a global leader in medical technologies and, together with our

Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Fri, 04 Sep 2026 18:32:00 -0400

About Stryker

Stryker is a global leader in medical technologies and, together with our

Form 4 STRYKER CORP For: Jun 26 Filed by: BRAINERD MARY K

Wed, 02 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260902/27019023.html

Stryker completes first surgery using FDA-cleared Apple Vision Pro app

Tue, 01 Sep 2026 09:05:40 -0400

Stryker (NYSE: SYK) announced the completion of the first surgical procedure using its SportSuite Vision application on Apple Vision Pro, performed at Duke Health. The procedure was a hip arthroscopy, according to a company press release.

The FDA granted De Novo authorization for SportSuite Vision on July 17, making it what the agency designated as the first application authorized for intraoperative use with Apple Vision Pro. De Novo authorization is a regulatory pathway for novel, low-to-moderate risk medical devices.

SportSuite Vision displays arthroscopic video alongside HipCheck, HipMap, and CT imaging within the Apple Vision Pro headset, consolidating multiple data sources into a

Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center

Tue, 01 Sep 2026 09:05:00 -0400

SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information

Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center.
Stryker received FDA De Novo authorization for the first surgical application for intraoperative use with Apple Vision Pro, SportSuite Vision.
SportSuite Vision brings arthroscopic video, HipCheck, HipMap and CT imaging into a customizable spatial computing environment, helping surgeons access critical clinical information within one ergonomic field of view and streamline operating room workflows.

Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center

Tue, 01 Sep 2026 09:05:00 -0400

SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information

Stryker announced the successful completion of the first surgical procedure, a hip arthroscopy, using SportSuite Vision on Apple Vision Pro at a leading academic medical center.
Stryker received FDA De Novo authorization for the first surgical application for intraoperative use with Apple Vision Pro, SportSuite Vision.
SportSuite Vision brings arthroscopic video, HipCheck, HipMap and CT imaging into a customizable spatial computing environment, helping surgeons access critical clinical information within one ergonomic field of view and streamline operating room workflows.

Stryker agrees to acquire ZuriMED to expand shoulder portfolio

Mon, 31 Aug 2026 16:05:07 -0400

Stryker (NYSE: SYK) has signed a definitive agreement to acquire ZuriMED, a privately held medical device company that developed the FiberLocker System, a soft tissue augmentation technology for rotator cuff repair.

The FiberLocker System is designed to reduce a key clinical failure mode in rotator cuff repair by providing increased biomechanical strength during augmentation procedures. The technology is already commercialized.

The acquisition is intended to expand Stryker's shoulder portfolio across both sports medicine and arthroplasty segments. Rotator cuff augmentation is described as one of the faster-growing areas in sports medicine, according to data cited from Mordor Intelligence.

Andy Pierce, Group President of MedSurg

Stryker agrees to acquire ZuriMED to expand shoulder portfolio

Mon, 31 Aug 2026 16:05:07 -0400

Andy Pierce, Group President of MedSurg

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

Mon, 31 Aug 2026 16:05:00 -0400

Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) --

Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.
The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.
The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one of the fastest-growing segments in sports medicine.

Stryker (NYSE:SYK), a global leader in medical technologies, announced

Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering

Mon, 31 Aug 2026 16:05:00 -0400

Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) --

Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides a novel approach for rotator cuff augmentation designed for increased biomechanical strength.
The acquisition strengthens Stryker’s shoulder portfolio, enhancing its ability to support specialists across the continuum of care.
The FiberLocker System is a soft tissue augmentation technology designed to reduce the occurrence of a key clinical failure mode in rotator cuff repair, one of the fastest-growing segments in sports medicine.

Stryker (NYSE:SYK), a global leader in medical technologies, announced

Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 15:00:00 -0400

Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.

Preston Wells, Vice President, Chief Financial Officer and Nick Mead, Vice President, Investor Relations will also participate in a fireside chat session at 2:15 p.m. (Eastern time). A simultaneous live audio webcast and replay of the session can be accessed at Stryker - Events & Presentations.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven

Stryker to participate in the 2026 Wells Fargo Healthcare Conference

Thu, 27 Aug 2026 15:00:00 -0400

Portage, Michigan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at the Encore Boston Harbor.

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven

Form 4 STRYKER CORP For: Aug 21 Filed by: Crotty Dylan Bram

Wed, 26 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260826/26982305.html

Form 4 STRYKER CORP For: Aug 21 Filed by: Crotty Dylan Bram

Wed, 26 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260826/26982305.html

Stryker (SYK) 1900 contracts of September 340 calls trade

Tue, 25 Aug 2026 15:16:51 -0400

Stryker (NYSE: SYK) 30-day option implied volatility is at 29; compared to its 52-week of 18 to 40 with a focus on 1900 contracts of September 340 calls.

Form 4 STRYKER CORP For: Aug 18 Filed by: STRYKER RONDA E

Thu, 20 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957158.html

Form 4 STRYKER CORP For: Aug 18 Filed by: STRYKER RONDA E

Thu, 20 Aug 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957158.html